Lantheus Holdings, Inc. (NASDAQ:LNTH) insider Cesare Orlandi sold 18,000 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $16.69, for a total value of $300,420.00. Following the completion of the transaction, the insider now directly owns 87,078 shares in the company, valued at approximately $1,453,331.82. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Lantheus Holdings, Inc. (NASDAQ:LNTH) remained flat at $16.40 during trading on Thursday. The stock had a trading volume of 766,743 shares. The company has a market capitalization of $612.54 million, a P/E ratio of 22.40 and a beta of 0.94. Lantheus Holdings, Inc. has a 52-week low of $7.18 and a 52-week high of $20.45. The stock’s 50 day moving average is $17.54 and its 200-day moving average is $15.24.

Lantheus Holdings (NASDAQ:LNTH) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.18. The business had revenue of $88.83 million for the quarter, compared to analyst estimates of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. Lantheus Holdings’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.24 earnings per share. Equities research analysts forecast that Lantheus Holdings, Inc. will post $1.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/09/07/lantheus-holdings-inc-lnth-insider-sells-300420-00-in-stock.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Lantheus Holdings by 87.5% during the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock valued at $26,093,000 after purchasing an additional 689,954 shares during the period. Marshall Wace North America L.P. raised its holdings in shares of Lantheus Holdings by 1,214.5% during the second quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock valued at $18,975,000 after purchasing an additional 973,977 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Lantheus Holdings by 12.6% during the second quarter. Renaissance Technologies LLC now owns 691,000 shares of the medical equipment provider’s stock valued at $12,196,000 after purchasing an additional 77,200 shares during the period. State Street Corp raised its holdings in shares of Lantheus Holdings by 3,932.8% during the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after purchasing an additional 601,714 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Lantheus Holdings by 79.8% during the second quarter. Dimensional Fund Advisors LP now owns 524,540 shares of the medical equipment provider’s stock valued at $9,258,000 after purchasing an additional 232,856 shares during the period. Hedge funds and other institutional investors own 84.35% of the company’s stock.

Several brokerages recently commented on LNTH. BidaskClub downgraded Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Zacks Investment Research raised Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a research note on Thursday, August 3rd. Cantor Fitzgerald began coverage on Lantheus Holdings in a research note on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Lantheus Holdings in a research note on Friday, June 30th. Finally, Credit Suisse Group raised their price objective on Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $18.60.

Lantheus Holdings Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Insider Buying and Selling by Quarter for Lantheus Holdings (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.